Is Lineage Cell Therapeutics stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Lineage Cell Therapeutics 10 years ago, but if you had invested on Monday 25th of November 2019 when the price was ILA3.13, you would have made a profit of ILA262.27 per share or 8 379.23%
Yes, the average daily trading liquidity for Lineage Cell Therapeutics is ILA16 855 thousand. You should therefore be able to get in and out of your positions relatively fast.
Lineage Cell Therapeutics has no real debt, which is good in periods of high inflation. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Lineage Cell Therapeutics to be medium [0.7 of 1]
US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.